Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | F2R | P25116 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8619629 | 0.86 | MAPK1 (0.60) | ALDH1A1MAPK1RAB9ALMNAHTT | |
| SCHEMBL28063097 | 0.85 | MAPK1 (0.67) | KMT2AALDH1A1L3MBTL1MAPK1RAB9A | |
| SCHEMBL1116453 | 0.83 | LMNA (0.58) | KMT2AALDH1A1L3MBTL1MAPK1RAB9A | |
| SCHEMBL5360905 | 0.82 | L3MBTL1 (0.58) | KMT2AALDH1A1L3MBTL1MAPK1RAB9A | |
| SCHEMBL24692098 | 0.82 | ALDH1A1 (0.49) | KMT2AALDH1A1L3MBTL1RAB9AMEN1 | |
| SCHEMBL11923480 | 0.81 | GAA (0.47) | KMT2AALDH1A1L3MBTL1MAPK1RAB9A | |
| SCHEMBL15145819 | 0.81 | CA1 (0.62) | KMT2AALDH1A1L3MBTL1MAPK1RAB9A | |
| SCHEMBL15338073 | 0.81 | L3MBTL1 (0.57) | KMT2AALDH1A1L3MBTL1MAPK1RAB9A | |
| SCHEMBL3865714 | 0.81 | L3MBTL1 (0.61) | KMT2AALDH1A1L3MBTL1MAPK1RAB9A | |
| SCHEMBL1562128 | 0.81 | ALDH1A1 (0.57) | KMT2AALDH1A1L3MBTL1MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-7632820-B2 | 4'-desoxy-4'-(phenylamino-carbonyl-hydrazono)-avermectin B1 monosaccharide; biocidal, very broad spectrum at low concentrations; endo-/ectopararsiticides in humans; insecticides; nematocides; miticides; agriculture; crops; veterinary medicine | MERIAL LIMITED (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632820-B2 | 4'-desoxy-4'-(phenylamino-carbonyl-hydrazono)-avermectin B1 monosaccharide; biocidal, very broad spectrum at low concentrations; endo-/ectopararsiticides in humans; insecticides; nematocides; miticides; agriculture; crops; veterinary medicine | MERIAL LIMITED (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| EP-0458197-A2 | Use of N-haloamides as photoinitiators for free-radical polymerizations | MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) | 1991-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | KMT2A 2755/4885ALDH1A1 1477/4885L3MBTL1 3806/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | KMT2A 2755/4885ALDH1A1 1477/4885L3MBTL1 3806/4885 |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | KMT2A 880/4885ALDH1A1 4025/4885L3MBTL1 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.